Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics Holdings Ltd. reports a significant quarterly revenue increase to $4.0 million, a 135% rise from the previous quarter, largely attributed to the success of their ViraDx and FebriDx products and a lucrative IP agreement with Hologic. The company also achieved positive cash flow, with cash receipts totaling $6.7 million, bolstered by a $5.0 million payment from Hologic. Enhanced distribution through a new agreement with Henry Schein is set to further bolster the U.S. market presence of the FebriDx product.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
